Nuvectis Pharma (NVCT) Competitors $9.05 -0.41 (-4.33%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$8.35 -0.70 (-7.73%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NVCT vs. XNCR, ZYME, XERS, PAHC, GYRE, OCS, REPL, COGT, DAWN, and EOLSShould you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Xencor (XNCR), Zymeworks (ZYME), Xeris Biopharma (XERS), Phibro Animal Health (PAHC), Gyre Therapeutics (GYRE), Oculis (OCS), Replimune Group (REPL), Cogent Biosciences (COGT), Day One Biopharmaceuticals (DAWN), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. Nuvectis Pharma vs. Xencor Zymeworks Xeris Biopharma Phibro Animal Health Gyre Therapeutics Oculis Replimune Group Cogent Biosciences Day One Biopharmaceuticals Evolus Nuvectis Pharma (NASDAQ:NVCT) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership. Do institutionals and insiders believe in NVCT or XNCR? 96.8% of Nuvectis Pharma shares are owned by institutional investors. 35.8% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 5.2% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer NVCT or XNCR? Xencor received 495 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 92.31% of users gave Nuvectis Pharma an outperform vote while only 73.16% of users gave Xencor an outperform vote. CompanyUnderperformOutperformNuvectis PharmaOutperform Votes1292.31% Underperform Votes17.69%XencorOutperform Votes50773.16% Underperform Votes18626.84% Does the media prefer NVCT or XNCR? In the previous week, Xencor had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 6 mentions for Xencor and 3 mentions for Nuvectis Pharma. Xencor's average media sentiment score of 0.41 beat Nuvectis Pharma's score of 0.25 indicating that Xencor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xencor 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts rate NVCT or XNCR? Nuvectis Pharma presently has a consensus target price of $15.67, indicating a potential upside of 73.11%. Xencor has a consensus target price of $34.38, indicating a potential upside of 285.37%. Given Xencor's stronger consensus rating and higher possible upside, analysts clearly believe Xencor is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Xencor 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is NVCT or XNCR more profitable? Nuvectis Pharma has a net margin of 0.00% compared to Xencor's net margin of -232.77%. Xencor's return on equity of -30.92% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Nuvectis PharmaN/A -155.80% -104.02% Xencor -232.77%-30.92%-21.74% Which has better valuation & earnings, NVCT or XNCR? Nuvectis Pharma has higher earnings, but lower revenue than Xencor. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvectis PharmaN/AN/A-$22.26M-$1.11-8.15Xencor$110.49M5.69-$126.09M-$3.51-2.54 Which has more risk and volatility, NVCT or XNCR? Nuvectis Pharma has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. SummaryXencor beats Nuvectis Pharma on 12 of the 18 factors compared between the two stocks. Remove Ads Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCT vs. The Competition Export to ExcelMetricNuvectis PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$211.70M$6.73B$5.54B$7.50BDividend YieldN/A2.79%4.86%4.04%P/E Ratio-7.806.9923.2418.07Price / SalesN/A198.60361.2586.83Price / CashN/A65.6738.1634.64Price / Book12.935.926.493.99Net Income-$22.26M$142.37M$3.21B$247.18M7 Day Performance-13.48%-7.24%-4.91%-4.25%1 Month Performance42.74%-10.45%-0.08%-6.87%1 Year Performance17.38%-14.58%6.40%-3.73% Nuvectis Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCTNuvectis Pharma2.425 of 5 stars$9.05-4.3%$15.67+73.1%+9.7%$211.70MN/A-7.808Analyst ForecastNews CoverageGap DownXNCRXencor3.5993 of 5 stars$12.95-1.9%$34.38+165.4%-58.6%$912.48M$110.49M-4.05280Gap DownZYMEZymeworks2.6049 of 5 stars$13.05+2.6%$21.00+60.9%+22.0%$907.98M$76.30M-8.70460Insider TradePositive NewsGap DownXERSXeris Biopharma3.784 of 5 stars$5.87+1.0%$5.92+0.8%+134.6%$903.63M$203.07M-13.04290Gap DownHigh Trading VolumePAHCPhibro Animal Health3.6145 of 5 stars$22.06+0.7%$21.00-4.8%+56.4%$893.50M$1.11B45.961,860Positive NewsGap DownGYREGyre Therapeutics0.1799 of 5 stars$9.21-5.1%N/A-60.4%$862.17M$105.76M184.2040Gap DownHigh Trading VolumeOCSOculis2.0463 of 5 stars$19.61+0.2%$29.50+50.4%+62.7%$856.21M$980,000.00-10.162REPLReplimune Group3.553 of 5 stars$11.05+2.1%$19.43+75.8%+11.8%$851.02MN/A-3.60210Positive NewsGap DownCOGTCogent Biosciences2.0497 of 5 stars$7.40+3.4%$14.43+95.0%-22.6%$842.49MN/A-2.9880Gap DownDAWNDay One Biopharmaceuticals2.9829 of 5 stars$8.31+1.0%$34.57+316.0%-50.6%$842.26M$131.16M-8.0760Analyst ForecastGap DownEOLSEvolus3.7308 of 5 stars$13.00-0.2%$24.67+89.7%-16.1%$826.63M$266.27M-14.29170Gap Down Remove Ads Related Companies and Tools Related Companies XNCR Alternatives ZYME Alternatives XERS Alternatives PAHC Alternatives GYRE Alternatives OCS Alternatives REPL Alternatives COGT Alternatives DAWN Alternatives EOLS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVCT) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NVCT Stock Free NVCT Stock Alerts